| Primary |
| Hiv Infection |
57.3% |
| Antiviral Prophylaxis |
18.2% |
| Antiretroviral Therapy |
5.9% |
| Antiviral Treatment |
3.7% |
| Drug Use For Unknown Indication |
3.4% |
| Acquired Immunodeficiency Syndrome |
2.2% |
| Product Used For Unknown Indication |
1.9% |
| Prophylaxis Against Hiv Infection |
1.9% |
| Prophylaxis |
1.5% |
| Drug Exposure During Pregnancy |
1.4% |
| Hiv Test Positive |
0.3% |
| Trigeminal Neuralgia |
0.3% |
| Tuberculosis |
0.3% |
| Cerebral Toxoplasmosis |
0.2% |
| Congenital Hiv Infection |
0.2% |
| Drug Dependence |
0.2% |
| Systemic Antiviral Treatment |
0.2% |
| Toxoplasmosis |
0.2% |
| Viral Infection |
0.2% |
| Anaesthesia Procedure |
0.2% |
|
| Drug Exposure During Pregnancy |
15.0% |
| Premature Baby |
10.0% |
| Thrombocytopenia |
7.1% |
| Neutropenia |
6.4% |
| Foetal Exposure During Pregnancy |
4.3% |
| Maternal Drugs Affecting Foetus |
4.3% |
| Overdose |
4.3% |
| Pre-eclampsia |
4.3% |
| Stillbirth |
4.3% |
| Tremor |
4.3% |
| Anaemia |
3.6% |
| Intra-uterine Death |
3.6% |
| Necrotising Colitis |
3.6% |
| Pyrexia |
3.6% |
| Small For Dates Baby |
3.6% |
| Strabismus |
3.6% |
| Ventricular Hypertrophy |
3.6% |
| Ventricular Septal Defect |
3.6% |
| Vomiting |
3.6% |
| Weight Decreased |
3.6% |
|
| Secondary |
| Hiv Infection |
52.5% |
| Antiretroviral Therapy |
6.8% |
| Drug Exposure During Pregnancy |
5.9% |
| Maternal Exposure Timing Unspecified |
5.3% |
| Product Used For Unknown Indication |
4.4% |
| Acquired Immunodeficiency Syndrome |
4.3% |
| Antiviral Prophylaxis |
4.1% |
| Drug Use For Unknown Indication |
3.2% |
| Hiv Test Positive |
3.1% |
| Antiviral Treatment |
2.3% |
| Prophylaxis Against Hiv Infection |
2.1% |
| Maternal Exposure During Pregnancy |
1.3% |
| Human Immunodeficiency Virus Transmission |
0.8% |
| Prophylaxis |
0.8% |
| Hypertension |
0.7% |
| Depression |
0.6% |
| Plasmablastic Lymphoma |
0.6% |
| Trigeminal Neuralgia |
0.5% |
| Hepatitis C |
0.4% |
| Lymph Node Tuberculosis |
0.4% |
|
| Drug Exposure During Pregnancy |
15.1% |
| Premature Baby |
9.8% |
| Pregnancy |
8.6% |
| Foetal Exposure During Pregnancy |
7.0% |
| Thrombocythaemia |
5.8% |
| Thrombocytopenia |
5.4% |
| Neutropenia |
4.2% |
| Strabismus |
4.2% |
| White Blood Cell Count Decreased |
4.2% |
| Maternal Exposure During Pregnancy |
3.8% |
| Threatened Labour |
3.8% |
| Vomiting |
3.6% |
| Anaemia |
3.2% |
| Diabetes Mellitus |
3.2% |
| Premature Rupture Of Membranes |
3.2% |
| Ventricular Septal Defect |
3.2% |
| Vitamin B12 Deficiency |
3.2% |
| Small For Dates Baby |
3.0% |
| Trisomy 21 |
3.0% |
| Talipes |
2.8% |
|
| Concomitant |
| Hiv Infection |
57.3% |
| Drug Use For Unknown Indication |
7.1% |
| Acquired Immunodeficiency Syndrome |
6.1% |
| Antiviral Treatment |
4.5% |
| Maternal Exposure During Pregnancy |
3.3% |
| Antiretroviral Therapy |
2.9% |
| Antiviral Prophylaxis |
2.5% |
| Prophylaxis Against Hiv Infection |
2.4% |
| Product Used For Unknown Indication |
2.2% |
| Hypertension |
2.1% |
| Exposure During Pregnancy |
1.3% |
| Antifungal Prophylaxis |
1.1% |
| Hepatitis C |
1.1% |
| Convulsion Prophylaxis |
1.0% |
| Asthma |
0.9% |
| Factor Viii Deficiency |
0.9% |
| Prophylaxis |
0.9% |
| Maternal Exposure Timing Unspecified |
0.9% |
| Insomnia |
0.8% |
| Drug Exposure During Pregnancy |
0.8% |
|
| Drug Exposure During Pregnancy |
8.5% |
| Pregnancy |
8.5% |
| Premature Baby |
8.0% |
| Hyperlipidaemia |
7.0% |
| Polydactyly |
7.0% |
| Pyrexia |
7.0% |
| Rash |
5.5% |
| Foetal Exposure During Pregnancy |
5.0% |
| Neutropenia |
5.0% |
| Renal Failure Acute |
5.0% |
| Vomiting |
5.0% |
| Thrombocytopenia |
4.0% |
| Hepatic Function Abnormal |
3.5% |
| Spinal X-ray Abnormal |
3.5% |
| Jaundice |
3.0% |
| Maternal Drugs Affecting Foetus |
3.0% |
| Premature Rupture Of Membranes |
3.0% |
| Suicide Attempt |
3.0% |
| Talipes |
3.0% |
| Visceral Leishmaniasis |
3.0% |
|
| Interacting |
| Product Used For Unknown Indication |
38.9% |
| Tuberculosis |
22.2% |
| Hiv Infection |
16.7% |
| Antifungal Prophylaxis |
5.6% |
| Depression |
5.6% |
| Insomnia |
5.6% |
| Vitamin Supplementation |
5.6% |
|
| Hallucination, Auditory |
50.0% |
| Visual Acuity Reduced |
50.0% |
|
